HER-2/neu基因高表达及靶向治疗  

Over-expression of HER-2/neu and targeted therapy

在线阅读下载全文

作  者:陈宇萍[1] 

机构地区:[1]海军总医院基础医学研究中心,北京100048

出  处:《生命科学》2010年第1期69-73,共5页Chinese Bulletin of Life Sciences

摘  要:HER-2/neu癌基因在许多肿瘤,如乳腺癌、卵巢癌、非小细胞肺癌等肿瘤中高表达,在肿瘤的发生与发展中起重要作用,与肿瘤的转化、转移、复发、预后差、患者生存期缩短有关。HER-2/neu在乳腺癌过度表达率约为20%~30%,编码蛋白P185HER2属生长因子受体家族,抗P185HER2单克隆抗体(Herceptin)作为靶向药物已临床应用治疗HER2/neu高表达乳腺癌。HER-2/neu oncogene is overexpressed in many kinds of tumors like breast cancer, ovarian cancer, nonsmall-cell lung cancer(NSCLC). Overexpression of HER-2/neu has significant effect on tumor occuring and development, it is associated with tumor inversion, metastasis, recuring, poorer prognosis and patient's shortening of life. HER-2/neu is overexpressed in approximately 20%-30% patients with breast cancer. The coding protein P185HER2 of HER-2/neu is a member of the human epidermal growth factor receptor family. Monoclonal antibody of P185HER2(Herceptin) is clinically used as a targeted drug for HER-2/neu overexpressed breast cancer.

关 键 词:HER-2/NEU基因 P185HER2 靶向治疗 

分 类 号:R730.59[医药卫生—肿瘤] R737.9[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象